SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 66 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,941,538 | +19.2% | 143,280 | +38.2% | 0.23% | +5.0% |
| Q1 2024 | $2,468,298 | +13.5% | 103,710 | +3.0% | 0.22% | +17.8% |
| Q4 2023 | $2,175,025 | +11.4% | 100,649 | -25.1% | 0.18% | -18.5% |
| Q3 2023 | $1,952,417 | -17.1% | 134,464 | +19.6% | 0.23% | -7.7% |
| Q2 2023 | $2,353,872 | +17.1% | 112,464 | +18.1% | 0.25% | +2.9% |
| Q1 2023 | $2,010,814 | +23.1% | 95,209 | +48.3% | 0.24% | 0.0% |
| Q4 2022 | $1,634,068 | +7.0% | 64,207 | +1.0% | 0.24% | +16.0% |
| Q3 2022 | $1,527,000 | +31.1% | 63,551 | +5.0% | 0.21% | +35.5% |
| Q2 2022 | $1,165,000 | +5.5% | 60,551 | -4.7% | 0.15% | +15.2% |
| Q1 2022 | $1,104,000 | +348.8% | 63,516 | +81.3% | 0.13% | +407.7% |
| Q2 2018 | $246,000 | -52.9% | 35,027 | -4.6% | 0.03% | -60.0% |
| Q1 2018 | $522,000 | -28.3% | 36,714 | -55.8% | 0.06% | -13.3% |
| Q4 2017 | $728,000 | +16.3% | 83,139 | +55.3% | 0.08% | -13.8% |
| Q3 2017 | $626,000 | -19.0% | 53,532 | -3.3% | 0.09% | -16.3% |
| Q2 2017 | $773,000 | – | 55,368 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $19,588,000 | 3.91% |
| Ghost Tree Capital, LLC | 575,000 | $10,988,000 | 3.21% |
| Avidity Partners Management LP | 4,823,400 | $92,175,000 | 2.04% |
| BVF INC/IL | 2,486,429 | $47,516,000 | 1.85% |
| FRAZIER MANAGEMENT LLC | 1,188,135 | $22,705,000 | 1.82% |
| Nantahala Capital Management | 2,657,159 | $50,778,000 | 1.60% |
| Boxer Capital, LLC | 2,287,782 | $43,720,000 | 1.53% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,939,000 | 1.39% |
| SPHERA FUNDS MANAGEMENT LTD. | 750,603 | $14,344,000 | 1.20% |
| PFM Health Sciences, LP | 1,856,738 | $35,482,000 | 1.04% |